T1	p 92 114	stable COPD patients .
T2	p 129 158	COPD patients , reversibility
T3	p 594 763	, 60 COPD patients underwent dyspnea evaluation ( VAS score ) and pulmonary function testing at baseline and one hour after placebo or 300?g indacaterol administration .
T4	i 718 763	placebo or 300?g indacaterol administration .
T5	i 1352 1367	bronchodilators
T6	i 1370 1381	?sRAW-based
T7	o 254 268	vital capacity
T8	o 363 385	dynamic hyperinflation
T9	o 388 423	gas trapping , and possibly dyspnea
T10	o 623 686	dyspnea evaluation ( VAS score ) and pulmonary function testing
T11	o 901 949	of intrathoracic gas volume ( ?ITGV ) ( r=0.61 ;
T12	o 954 989	0.001 ) , residual volume ( ?RV ) (
T13	o 1013 1051	?FVC ( r=0.44 ; p=0.001 ) , and ?VAS (
T14	o 1169 1220	of ?ITGV ( p=0.002 ) , ?RV ( p=0.023 ) , and ?VAS (
T15	o 1504 1518	lung mechanics
T16	o 1523 1530	dyspnea